A new trading day began on Friday, with BioXcel Therapeutics Inc (NASDAQ: BTAI) stock price down -10.80% from the previous day of trading, before settling in for the closing price of $0.57. BTAI’s price has ranged from $0.50 to $4.17 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 53.60%. Meanwhile, its annual earnings per share averaged 72.40%. With a float of $34.07 million, this company’s outstanding shares have now reached $42.75 million.
Considering the fact that the conglomerate employs 74 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 4.13%, operating margin of -3295.61%, and the pretax margin is -3119.33%.
BioXcel Therapeutics Inc (BTAI) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of BioXcel Therapeutics Inc is 20.29%, while institutional ownership is 7.43%. The most recent insider transaction that took place on Oct 03 ’24, was worth 3,450. In this transaction Chief Commercial Officer of this company sold 6,272 shares at a rate of $0.55, taking the stock ownership to the 19,011 shares. Before that another transaction happened on Oct 03 ’24, when Company’s See Remarks sold 6,863 for $0.55, making the entire transaction worth $3,775. This insider now owns 23,770 shares in total.
BioXcel Therapeutics Inc (BTAI) Recent Fiscal highlights
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.76 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.45 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 72.40% per share during the next fiscal year.
BioXcel Therapeutics Inc (NASDAQ: BTAI) Trading Performance Indicators
Here are BioXcel Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.51.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.15, a number that is poised to hit -0.36 in the next quarter and is forecasted to reach -1.35 in one year’s time.
Technical Analysis of BioXcel Therapeutics Inc (BTAI)
Compared to the last year’s volume of 0.82 million, its volume of 0.62 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 26.84%. Additionally, its Average True Range was 0.06.
During the past 100 days, BioXcel Therapeutics Inc’s (BTAI) raw stochastic average was set at 2.16%, which indicates a significant decrease from 7.04% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 119.94% in the past 14 days, which was higher than the 92.62% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5995, while its 200-day Moving Average is $1.5465. Nevertheless, the first resistance level for the watch stands at $0.5437 in the near term. At $0.5785, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.6053. If the price goes on to break the first support level at $0.4821, it is likely to go to the next support level at $0.4553. Now, if the price goes above the second support level, the third support stands at $0.4205.
BioXcel Therapeutics Inc (NASDAQ: BTAI) Key Stats
With a market capitalization of 19.41 million, the company has a total of 42,748K Shares Outstanding. Currently, annual sales are 1,380 K while annual income is -179,050 K. The company’s previous quarter sales were 210 K while its latest quarter income was -13,650 K.
